Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021

Publisher Name :
Date: 30-Dec-2021
No. of pages: 4011
Inquire Before Buying

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2021, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 19, 154, 164, 5, 16, 306, 67 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 27, 8, 1, 49 and 29 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodol'ogy
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, 2021
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, 2021

List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
  • T-Cell Immunotherapy Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Product Type
    Published: 22-May-2022        Price: US 3500 Onwards        Pages: 84
    This report describes the global market size of T-Cell Immunotherapy from 2017 to 2021 and its CAGR from 2017 to 2021, and also forecasts its market size to the end of 2027 and its CAGR from 2022 to 2027. For geography segment, regional supply, demand, major players, price is presented from 2017 to 2027. This report cover following regions: North America South America Asia & Pacific Europe MEA The key countries for each regions are also inc......
  • 2022-2030 Report on Global Immunotherapy Market by Player, Region, Type, Application and Sales Channel
    Published: 17-May-2022        Price: US 2500 Onwards        Pages: 107
    This report studies the Immunotherapy market, covering market size for segment by type (Monoclonal Antibodies, Vaccines, etc.), by application (Cancer, Infectious Diseases, etc.), by sales channel (Direct Channel, Distribution Channel), by player (AbbVie, Merck, Pfizer, Roche, Bristol-Myers Squibb, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Immunotherapy f......
  • (Post-pandemic Era) - Global Cancer Immunomodulator Market Segment Research Report 2022
    Published: 13-May-2022        Price: US 2950 Onwards        Pages: 106
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • Global and United States Cancer Immunomodulator Market Report & Forecast 2022-2028
    Published: 11-May-2022        Price: US 4350 Onwards        Pages: 92
    Cancer Immunomodulator market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cancer Immunomodulator market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the Cancer Immunomodulator market size by......
  • Extrahepatic Bile Duct Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 51
    Extrahepatic Bile Duct Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Extrahepatic Bile Duct Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Extrahepatic Bile Duct Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extrahepatic Bile Duct Cancer, complete with analysis by Stage of D......
  • Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 68
    Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphoblastic Lymphoma, complete with analysis by Stage of Development, Drug Target, Mec......
  • Androgen-Sensitive Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 35
    Androgen-Sensitive Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Androgen-Sensitive Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Androgen-Sensitive Prostate Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Androgen-Sensitive Prostate Cancer, complete with an......
  • Ocular Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2000 Onwards        Pages: 112
    Ocular Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Ocular Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Rout......
  • Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
    Published: 02-May-2022        Price: US 2500 Onwards        Pages: 132
    Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics un......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs